Skip to main content
Log in

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sandrock A, Hotermans C, Richman S et al (2011) Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: Role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status [Poster AAN 2011]. P03.248

  2. Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 68:295–303

    Article  PubMed  Google Scholar 

  3. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387

    Article  PubMed  Google Scholar 

  4. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093–2109

    Article  PubMed  CAS  Google Scholar 

  5. Warnke C, Dehmel T, Posevitz-Fejfàr A et al (2011) Anti-JCV antibody prevalence in a german MS cohort [abstract]. Mult Scler 10(suppl):P520

    Google Scholar 

  6. Olsson T, Achiron A, Alfredsson L et al (2011) Prevalence of anti JCV antibodies in a multi-national cohort of multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P338

    Google Scholar 

  7. Bozic C, Richman S, Plavina T et al (2011) Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742–750

    Article  PubMed  Google Scholar 

  8. Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:836–846

    Article  Google Scholar 

  9. Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067–1074

    Article  PubMed  CAS  Google Scholar 

  10. Rudick RA, O’Connor PW, Polman CH et al (2009) Assessment of JC Virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304–310

    Article  Google Scholar 

  11. Bozic C, Subramanyam M, Paes D et al (2011) JCV epidemiology in MS: epidemiology on anti-JC virus antibody prevalence in multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P801

    Google Scholar 

  12. Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697–1704

    Article  PubMed  CAS  Google Scholar 

  13. Phan-Ba R, Lommers E, Tshibanda L (2011) MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83:284–286

    Google Scholar 

  14. Kappos L, Bates D, Edan G et al (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745–758

    Article  PubMed  CAS  Google Scholar 

  15. Sorensen PS, Bertolotto A, Edan G et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mutl Scler 18:143–152

    Article  Google Scholar 

Download references

Conflicts of interest

Prof. Duhamel and Drs. Ongagna, Collongues, Lacour, Fleury, Bertheloot and Giroux have nothing to disclose. Dr. Outteryck has received funding for travel from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries, Ltd., and Sanofi-Aventis, and speaker honoraria from Bayer Schering Pharma, Biogen Idec and Sanofi-Aventis. Dr. Zéphir has received funding for travel from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries, Ltd., and Sanofi-Aventis, and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries, Ltd., and Sanofi-Aventis. Prof. Vermersch serves on scientific advisory boards for Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries, Ltd., and Sanofi-Aventis; has received funding for travel and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceutical Industries, Ltd., Sanofi-Aventis and Merck Serono; and receives research support from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva Pharmaceutical Industries, Ltd., and Bayer Schering Pharma. Prof. de Sèze serves on the scientific advisory board for Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries, Ltd., and Sanofi-Aventis; has received funding for travel and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceutical Industries, Ltd., Sanofi-Aventis and Merck Serono; and receives research support from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva Pharmaceutical Industries, Ltd., and Bayer Schering Pharma.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olivier Outteryck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Outteryck, O., Ongagna, JC., Duhamel, A. et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 259, 2293–2298 (2012). https://doi.org/10.1007/s00415-012-6487-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6487-5

Keywords

Navigation